Ceriwastatyna (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ceriwastatyna" in Polish language version.

refsWebsite

Global rank Polish rank

9nih.gov

4^th place

7^th place

4doi.org

2^nd place

6^th place

2google.pl

low place

557^th place

1fda.gov

447^th place

1,118^th place

1web.archive.org

1^st place

1sigmaaldrich.com

924^th place

75^th place

1archive.ph

756^th place

32^nd place

1jlr.org

low place

1mp.pl

8,738^th place

165^th place

1ajmc.com

low place

1archive.org

6^th place

33^rd place

1medscape.com

719^th place

1,030^th place

1viamedica.pl

low place

585^th place

1ahajournals.org

3,608^th place

1,925^th place

ahajournals.org

circ.ahajournals.org

S. Bellosta, R. Paoletti, A. Corsini. Safety of statins: focus on clinical pharmacokinetics and drug interactions. „Circulation”. 109 (23 Suppl 1), s. III.50–III.57, 2004. DOI: 10.1161/01.CIR.0000131519.15067.1f. PMID: 15198967. (ang.).

ajmc.com

Michael B. Bottorff: Safety and Statins: Pharmacologic and Clinical Perspectives. 2004-11-01. [dostęp 2015-01-13].

archive.org

Kathleen Botham, Peter A. Mayes: Synteza, transport i wydalanie cholesterolu. W: Robert K. Murray, Daryl K. Granner, Victor W. Rodwell: Biochemia Harpera ilustrowana. Warszawa: Wydawnictwo Lekarskie PZWL, 2006, s. 283. ISBN 978-83-200-3573-5.

archive.ph

Japanese Antihyperlipidemic Market: New Statin Products and Their Marketing Strategies. Frost & Sullivan Market Insight, 2000. [dostęp 2014-11-11]. (ang.).

doi.org

Kuhlmann J., Mūck W., Bischoff H., Keutz E. von, Llewellyn M. Cerivastatin (BAY w 6228): A Novel HMG-CoA Reductase Inhibitor. „Cardiovascular Drug Revievs”. s. 236–263. DOI: 10.1111/j.1527-3466.1998.tb00357.x. (ang.).
R.Y. Mukhtar, J. Reid, J.P. Reckless. Pitavastatin. „Int J Clin Pract”. 59 (2), s. 239–252, Feb 2005. DOI: 10.1111/j.1742-1241.2005.00461.x. PMID: 15854203. (ang.).
B. Sadowitz, K.G. Maier, V. Gahtan. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease. „Vasc Endovascular Surg”. 44 (4), s. 241–251, 2010. DOI: 10.1177/1538574410362922. PMID: 20403949. (ang.).
S. Bellosta, R. Paoletti, A. Corsini. Safety of statins: focus on clinical pharmacokinetics and drug interactions. „Circulation”. 109 (23 Suppl 1), s. III.50–III.57, 2004. DOI: 10.1161/01.CIR.0000131519.15067.1f. PMID: 15198967. (ang.).

fda.gov

accessdata.fda.gov

Baycol (cerivastatin sodium tablets). Agencja Żywności i Leków. [dostęp 2014-12-06].

google.pl

books.google.pl

Vincent Gullo, Arnold L. Demain: Statins Fermentation Products for Cholesterol Control in Humans. W: Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds. Goutam Brahmachari (red.). CRC Press, 2013, s. 435–442. ISBN 978-1-4398-9167-4. [dostęp 2014-12-22]. (ang.).
Jie Jack Li, E. J. Corey: Drug Discovery: Practices, Processes, and Perspectives. New Jersey: John Wiley & Sons, s. 20–21. ISBN 978-0-470-94235-2.

jlr.org

Akira Endo. The discovery and development of HMG-CoA reductase inhibitors. „Journal of Lipid Research”. 33 (11), s. 1569–1582, 1992. PMID: 15531278. (ang.).

medscape.com

Katherine Rother: Bayer pulls cerivastatin from Japan, faces possible punitive damages in US and Germany. Medscape, 2001-08-28. [dostęp 2015-02-22]. (ang.).

mp.pl

Ceriwastatyna wycofana z obrotu. Medycyna Praktyczna, 2001-08-09. [dostęp 2014-10-15].

nih.gov

ncbi.nlm.nih.gov

R.Y. Mukhtar, J. Reid, J.P. Reckless. Pitavastatin. „Int J Clin Pract”. 59 (2), s. 239–252, Feb 2005. DOI: 10.1111/j.1742-1241.2005.00461.x. PMID: 15854203. (ang.).
Akira Endo. The discovery and development of HMG-CoA reductase inhibitors. „Journal of Lipid Research”. 33 (11), s. 1569–1582, 1992. PMID: 15531278. (ang.).
G.E. Stokker, A.W. Alberts, P.S. Anderson, E.J. Cragoe i inni. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 3. 7-(3,5-Disubstituted [1,1'-biphenyl]-2-yl)-3,5-dihydroxy-6-heptenoic acids and their lactone derivatives. „J Med Chem”. 29 (2), s. 170–181, 1986. PMID: 3950902.
C.D. Furberg, B. Pitt. Withdrawal of cerivastatin from the world market. „Curr Control Trials Cardiovasc Med”. 2 (5), s. 205–207, 2001. PMID: 11806796.
A. Endo. A historical perspective on the discovery of statins. „Proc Jpn Acad Ser B Phys Biol Sci”. 86 (5), s. 484–493, 2010. PMID: 20467214. (ang.).
B. Sadowitz, K.G. Maier, V. Gahtan. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease. „Vasc Endovascular Surg”. 44 (4), s. 241–251, 2010. DOI: 10.1177/1538574410362922. PMID: 20403949. (ang.).
S. Bellosta, R. Paoletti, A. Corsini. Safety of statins: focus on clinical pharmacokinetics and drug interactions. „Circulation”. 109 (23 Suppl 1), s. III.50–III.57, 2004. DOI: 10.1161/01.CIR.0000131519.15067.1f. PMID: 15198967. (ang.).

pubchem.ncbi.nlm.nih.gov

Cerivastatin, [w:] PubChem [online], United States National Library of Medicine, CID: 446156 (ang.).
Cerivastatin, [w:] ChemIDplus [online], United States National Library of Medicine [dostęp 2015-01-30] (ang.).

sigmaaldrich.com

Cerivastatin sodium salt hydrate [online], karta charakterystyki produktu Sigma-Aldrich, 27 kwietnia 2022, numer katalogowy: SML0005 [dostęp 2024-03-08] . (przeczytaj, jeśli nie wyświetla się prawidłowa wersja karty charakterystyki)

viamedica.pl

czasopisma.viamedica.pl

Renata Główczyńska, Wojciech Paluch, Krzysztof J. Filipiak. Działania niepożądane statyn. „Choroby Serca i Naczyń”. 4 (1), s. 18–34, 2007. (ang.).

web.archive.org

Cerivastatin, Sodium Salt (CAS 143201-11-0). Santa Cruz Biotechnology. [dostęp 2014-12-25]. (ang.).